Amid Torrent Of Next-Gen Anticoagulant Data, Trial Design Differences Complicate Comparisons Between Potential Competitors
Executive Summary
As pivotal data on the new generation of anticoagulants continue to become public, differences in trial design and population are confusing attempts to predict competitive positioning for the new agents.
You may also be interested in...
Boehringer Will Test How Pradaxa Stacks Up To The Competition In Real-World Study
Global observational study is assessing real-world experience with Pradaxa and other anticoagulants in patients with newly diagnosed atrial fibrillation and at risk of stroke. Results are due in 2020.
Boehringer Will Test How Pradaxa Stacks Up To The Competition In Real-World Study
Global observational study is assessing real-world experience with Pradaxa and other anticoagulants in patients with newly diagnosed atrial fibrillation who are at risk of stroke. Results are due in 2020.
FDA Approval Of Xarelto Bodes Well For Drug’s Future Expansion
The July 1 approval of Johnson & Johnson’s novel anticoagulant Xarelto for prevention of deep vein thrombosis is an important step for J&J and its ex-U.S. partner Bayer AG as they gear up to play in the highly promising but increasingly complicated world of novel anticoagulants.